PRCT News & Analysis
2 articles
Market Mood
Procept BioRobotics (PRCT) Price Target Lowered by Jefferies
Jefferies has reduced its price target for Procept BioRobotics (PRCT) following a missed procedure target. This adjustment may reflect anticipated challenges for the company in meeting its growth expectations. It is significant as analysts' opinions often influence investor sentiment and stock performance. Investors should be aware of how such updates can impact the stock price and trading volume.
Read More: Procept BioRobotics (PRCT) Price Target Lowered by Jefferies
PROCEPT BioRobotics (PRCT) Trading at 4.5x Sales Amid Growth
As of June 17, PROCEPT BioRobotics Corporation (PRCT) shares traded at $20.91. The company reported quadrupled revenues since 2022, currently growing at approximately 30% year-over-year. Despite this growth, PRCT trades at 4.5 times sales, while peers like Intuitive Surgical (ISRG) previously traded in a range of 9-18 times sales. Analysts project that PRCT could see approximately 150% appreciation over three years if growth patterns similar to ISRG continue, although short-term sentiment remains mixed due to slightly below-expectation revenue guidance.
Read More: PROCEPT BioRobotics (PRCT) Trading at 4.5x Sales Amid Growth